Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (51-60 of 1,622) with videos related to

Pageof 163
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learnM Markman
Cleveland Clinic Journal of Medicine|September 1, 1996
What does tumor shrinkage mean to the patient receiving chemotherapy?M Markman
Cleveland Clinic Journal of Medicine|May 1, 1997
Ethical issues in clinical trials in oncologyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Clinical practice guidelines in oncology: pros and consM Markman
Seminars in Oncology|February 13, 2002
Second-line treatment of ovarian cancer with single-agent gemcitabineMaurie Markman
Annals of Medicine|August 1, 1996
Intraperitoneal chemotherapy in the treatment of ovarian cancerM Markman
Pediatrics in Review|August 4, 2009
Teething: facts and fictionLisa Markman
Current Oncology Reports|December 17, 2008
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progressionMaurie Markman
Nature Reviews. Clinical Oncology|September 30, 2009
Chemotherapy: Topotecan or treosulfan--that is the questionMaurie Markman
Dental Economics - Oral Hygiene|April 1, 1979
Why don't we eliminate patient pain?S Markman
Pageof 163

Showing results (51-60 of 1,622) with videos related to

Sort By:
Pageof 163
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learnM Markman
Cleveland Clinic Journal of Medicine|September 1, 1996
What does tumor shrinkage mean to the patient receiving chemotherapy?M Markman
Cleveland Clinic Journal of Medicine|May 1, 1997
Ethical issues in clinical trials in oncologyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Clinical practice guidelines in oncology: pros and consM Markman
Seminars in Oncology|February 13, 2002
Second-line treatment of ovarian cancer with single-agent gemcitabineMaurie Markman
Annals of Medicine|August 1, 1996
Intraperitoneal chemotherapy in the treatment of ovarian cancerM Markman
Pediatrics in Review|August 4, 2009
Teething: facts and fictionLisa Markman
Current Oncology Reports|December 17, 2008
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progressionMaurie Markman
Nature Reviews. Clinical Oncology|September 30, 2009
Chemotherapy: Topotecan or treosulfan--that is the questionMaurie Markman
Dental Economics - Oral Hygiene|April 1, 1979
Why don't we eliminate patient pain?S Markman
Pageof 163